Overview of Novocalmin

Property	Description
Active ingredient	Sodium Metamizole (Metamizolum natrium)
Pharmacological class	Non-opioid analgesic; Pyrazolone derivative
Origin	Synthetic
Common purpose	Pain relief, fever reduction, smooth muscle spasm relief
Available forms	Tablets, oral solution, suppositories, IV/IM injection

What is Novocalmin and its Active Ingredient?

Novocalmin is a pharmaceutical preparation whose core component is the potent synthetic compound Sodium Metamizole (Metamizolum natrium), known internationally as Dipyrone or Analgin. It is classified as a non-opioid analgesic and antipyretic, placing it in the pyrazolone derivative group of medicines. This medication is typically formulated as a single-component product, containing only the active ingredient and necessary pharmaceutical excipients. This structural classification highlights that Novocalmin operates via mechanisms distinct from common pain relievers like Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).

What Type of Medicine is Novocalmin? (Class and General Purpose)

Novocalmin belongs to the pharmacological class of Other analgesics and antipyretics, defined by its primary beneficial actions of strong pain relief and effective fever reduction. Its general purpose is to provide robust systemic symptomatic relief from physical discomfort and high body temperature. Metamizole is primarily employed for its potent analgesic and antipyretic effects, often when other treatments are insufficient. Beyond its pain and fever management capabilities, the drug is functionally distinguished by its characteristic spasmolytic effect, which promotes the relaxation of smooth muscles. This unique triple action makes Novocalmin particularly useful when the required relief includes addressing pain that is caused or intensified by muscle spasms.

Available Forms of Novocalmin

Novocalmin is available in multiple systemic dosage forms to accommodate various administration needs, including tablets, oral solution, and solutions prepared for parenteral delivery via intravenous (IV) or intramuscular (IM) injection, as well as suppositories. The availability of these various forms, particularly the injectable solutions, is necessary to deliver the active component, Sodium Metamizole, into the system efficiently. These forms necessitate different routes of administration, which may be oral, rectal, or parenteral, ensuring that the medication can be administered effectively in both routine and acute settings.

What side effects are possible with Novocalmin?

Possible Side Effects and Safety Information

The official safety profile for Novocalmin (Sodium Metamizole) is defined by its potential for rare, yet serious, adverse reactions affecting specific organ systems, as documented by government regulatory bodies.

Adverse Reaction Classifications

The frequency of side effects is categorized according to regulatory standards:

Uncommon: Adverse effects occurring in fewer than 1 in 100 people, such as Hypotension (low blood pressure) and Fixed drug eruption (a localized skin reaction).
Rare to Very Rare: Serious reactions occurring in very few individuals, including Leukopenia (low white blood cell count), Anaphylactoid reactions, and the extremely rare but potentially fatal Agranulocytosis (severe reduction in granulocytes).
Not Known: Serious reactions where frequency cannot be estimated from current data, such as Drug-Induced Liver Injury (acute hepatitis), Acute Renal Failure, and Circulatory Shock.

Serious Adverse Reactions and Safety Constraints

The most clinically significant documented safety risks are primarily related to the Blood and Lymphatic System and Immune System.

Agranulocytosis is a critical safety consideration, as this severe blood disorder is not related to the dose and may occur at any time during or shortly after treatment. Anaphylactic Shock, a potentially fatal severe allergic reaction, typically manifests within the first hour of administration. Other rare but serious effects include Bullous Skin Reactions (Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis).

Novocalmin is Contraindicated during the third trimester of pregnancy due to potential fetal risk. Caution is required in patients with existing hepatic or renal impairment, as the elimination of drug metabolites may be reduced, especially when using high or repeated doses.

Overdose and Emergency Response

Overdose and When to Seek Help

Novocalmin (Metamizole) is generally considered fairly safe in an overdose scenario. However, any suspected overdose is a medical emergency that requires prompt attention to ensure proper monitoring and management.

Overdose Response and Emergency Action

If an overdose is suspected, immediate medical attention is required. Contact a local emergency service or a poison control center right away. The main goal of overdose management is to provide supportive measures and limit the amount of the substance absorbed by the body.

Overdose Severity	Required Emergency Action
Considered fairly safe	Seek immediate medical help. Supportive measures are usually advised.

Clinical Management Focus

Treatment of an overdose focuses on accelerating the elimination of the substance from the body and managing any related symptoms. Official guidance outlines key procedural instructions for healthcare providers:

Supportive Measures: General supportive care is a standard recommendation in all overdose cases.
Limiting Absorption: Measures such as the administration of activated charcoal are typically advised to help limit the body’s absorption of the substance.
Accelerating Excretion: Procedures to hasten elimination, such as haemodialysis, are often advised by medical experts, depending on the severity and patient condition.

It is important to provide medical staff with the name of the medicine, the amount taken, and the time the overdose occurred.

Therapeutic Uses of Novocalmin

What Novocalmin Treats: Main Uses and Benefits

Novocalmin (Metamizole) is an analgesic medication that is commonly used across therapeutic domains where additional symptomatic support is needed. It is generally considered relevant for easing symptoms related to moderate to severe pain and fever that may not respond to other common treatments. This medication is designed to provide short-term, supportive relief, and may assist with maintaining functional stability during episodes of heightened distress.

The primary therapeutic indications for Novocalmin include managing pain following surgery or injuries, addressing severe acute and chronic pain, and providing relief for fever that is resistant to other standard treatments. The medicine is often applied during phases where the patient experiences heightened discomfort or tension.

“The medication helps address symptom clusters that may become intense or disruptive and interfere with daily functioning.”

This use covers conditions characterized by periods of heightened symptoms, where symptom clusters create noticeable functional strain. It may assist with maintaining functional stability and contributes to easing the overall symptom load, helping improve day-to-day comfort during periods of symptomatic fluctuation.

Quick Fact: Relief for Severe Discomfort Novocalmin is considered relevant for use in conditions where symptoms escalate temporarily and create a significant symptomatic burden.

Regulatory References

European Medicines Agency review of Metamizole

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Novocalmin (Metamizole) — Official Regulatory Information

Official regulatory guidelines define specific populations who are permitted to use Novocalmin and those for whom its use is strictly prohibited or restricted. This profile is based on mandatory exclusionary criteria found in official labeling.

Eligibility Scope

Category	Eligibility Classification (Official Regulatory Text)
Populations for whom use is allowed:	Adults and adolescents aged 15 years or older. Infants 3 months of age or older or over 5 kg.
Populations for whom use is contraindicated:	Patients with a prior history of metamizole-induced agranulocytosis or diseases of the haematopoietic system. Patients in the third trimester of pregnancy. Infants below the age of 3 months or under 5 kg.
Condition-specific eligibility rules:	Acute Intermittent Hepatic Porphyria and G6PD deficiency are contraindications. Use is restricted/conditional in patients with hepatic or renal impairment; multiple high doses should be avoided.
Pregnancy and lactation eligibility status:	Contraindicated in the third trimester. Conditional use in the first six months. Not recommended during breastfeeding; milk must be discarded for 48 hours following a single dose.

Eligibility Classifications (High-Level)

Category	Official Regulatory Classification
Eligibility severity classification:	Contraindicated (Absolute prohibition). Restricted Use/Caution Advised (Conditional or dose-limiting use). Not Recommended.

The official profile restricts use based on pre-existing blood disorders, metabolic conditions, and high-risk physiological states like late-stage pregnancy, thereby limiting eligibility to healthy adults, adolescents, and children who meet minimum age and weight requirements.

What should I know about interactions with other medicines?

Novocalmin’s official interaction profile centers on its impact on drug metabolism and specific pharmacodynamic interferences, as documented by regulatory authorities. The medicine is a pyrazolone derivative, and its use is formally contraindicated in patients with a history of bone marrow toxicity (agranulocytosis) induced by other Pyrazolone or Pyrazolidine derivatives.

The drug is a moderate to strong inducer of Cytochrome P450 (CYP) enzymes, particularly CYP3A4, CYP2B6, and CYP2C19. This pharmacokinetic induction reduces the plasma concentrations of co-administered medicines that are substrates of these enzymes. Substances explicitly documented to exhibit reduced exposure include Cyclosporine, Tacrolimus, Efavirenz, Methadone, Bupropion, Valproic Acid, and Sertraline, potentially leading to a decrease in their clinical effectiveness.

A specific pharmacodynamic interaction is noted with low-dose Acetylsalicylic Acid (ASA), where Novocalmin interferes with the intended antiplatelet effect of ASA. Official regulatory information recommends a time separation between the two medicines to mitigate this effect. Additionally, co-administration with other myelotoxic agents, such as high-dose Methotrexate, carries a documented additive risk of haematotoxicity. No specific interaction constraints are officially documented for food, alcohol, or herbal products.

Mechanism of Action

Modulation of Receptor-Mediated Signaling

Novocalmin primarily acts within domains involving receptor-mediated signaling, engaging mechanisms that regulate overactive or dysregulated cellular processes. This biological action leads to modification of processes driven by distinct signaling patterns, resulting in attenuation of heightened signaling output.

Engagement with Key Pathway Cascades

The drug modifies early molecular steps and can initiate or suppress signaling sequences that lead to downstream effects. This intervention affects mechanistic cascades where multiple layers of pathway activation occur, resulting in defined shifts in physiological parameters that correspond to the drug's activity.

Targeting Overactive Physiological Systems

Novocalmin is used to alter pathway activity that may escalate under certain conditions, influencing systems where specific transmitters or mediators dominate. This action results in the reduction of excessive mediator activity, modulating the equilibrium within targeted biological pathways to an altered state of signaling balance.

Dosage and Administration Information

The administration of Novocalmin (Sodium Metamizole) is strictly governed by quantitative and procedural parameters defined in official prescribing information, which outline its proper use. The medication is approved for systemic use via multiple routes, including oral (tablets or solution), rectal (suppositories), and parenteral (intravenous or intramuscular) injection.

Standard adult dosing is typically 500 mg to 1,000 mg per single administration. Dosing is executed as needed (PRN) for acute symptomatic relief, with a mandatory minimum interval of at least six hours between doses to prevent accumulation. The total daily intake is strictly limited and must not exceed 4,000 mg across all forms. The course of treatment is intended for short-term use only, strictly restricted to the duration of the acute symptoms being managed.

Administration Scope	Procedural and Quantitative Rules (Official Labeling)
Dosing Schedule & Frequency	Single doses up to 1,000 mg; administered up to four times daily; maintaining a minimum 6-hour interval.
Parenteral Specifics	IV injection must be administered slowly (e.g., over 3 -5 minutes) and is generally reserved for supervised, clinical settings. The injectable solution should not be mixed with other medicinal products.
Population Adjustments	Pediatric dosing is calculated precisely based on the patient’s body weight. Dose reduction or interval extension is officially required for patients with renal or hepatic impairment and often for older adults baker.

Oral forms may be taken independently of food, while adherence to all instructions regarding dose quantity, frequency, and duration is central to the officially published administration protocol.

Recent Clinical Evidence

Research evidence / Overview of studies for Novocalmin

Evidence for Acute Severe Pain and Colic

Research examining Sodium Metamizole (Novocalmin) in the context of acute severe pain has primarily consisted of short-term Randomized Controlled Trials (RCTs) and Systematic Reviews. These studies compared outcomes against controls and examined populations with severe discomfort, such as pain following surgery, injury, and conditions associated with tumor-related pain. For painful colic, studies explored outcomes related to muscle tension. Findings describe patterns observed in studies related to measured physical discomfort during the acute phase of the study, monitored via patient-reported outcomes.

Scientific literature indicates that long-term studies evaluating the medicine's effects over months or years are not well characterized. The evidence for continuous use in chronic conditions is limited, as many foundational trials focused on single-dose or short-course administration.

Evidence for High Fever Resistant to Standard Treatments

Novocalmin was evaluated for its application in the context of high fever. Research examined outcomes related to systemic or functional imbalance (fever), primarily through short-term RCTs that focused on the antipyretic effect. Research highlights changes measured during the study period related to measured temperature change. These findings contribute to understanding how patient-reported outcomes evolved in observed populations during an acute episode.

The full body of evidence regarding long-term use in recurring or persistent fever states remains limited. Data for certain groups, such as the pediatric population, remain insufficient for long-term outcomes, and research is ongoing to fully characterize the effects in these varying populations.

Research Gaps and Specific Populations

Research has been conducted across different demographics, including older adults in observational settings and the pediatric population (children) studied for postoperative care. For both groups, the data remain insufficient, and the follow-up durations were limited in many reports. Overall research gaps include a high prevalence of studies with modest sample sizes and the lack of comprehensive comparative evidence against every alternative treatment. Research does not determine whether an individual will respond similarly, as study results reflect the specific conditions under which they were conducted.

Frequently Asked Questions (FAQ)

Common questions about Novocalmin (FAQ)

Q: Is Novocalmin a painkiller or an anti-inflammatory drug?

A: Novocalmin is officially classified as a non-opioid analgesic (painkiller) and an antipyretic (fever reducer) with the added property of being a spasmolytic (muscle relaxant). Official product information notes that it is structurally different from traditional anti-inflammatory drugs (NSAIDs) and is not primarily used for its anti-inflammatory effects.

Q: What are the most common side effects of Novocalmin?

A: According to official regulatory documents, the most common side effects reported include feeling dizzy, experiencing nausea or upset stomach, and sometimes having a temporary drop in blood pressure (hypotension). The full product information lists all documented side effects, including rare, serious ones.

Q: Can Novocalmin be taken with other cold or flu medicines?

A: Official interaction profiles indicate that Novocalmin is known to induce certain liver enzymes (like CYP3A4 and CYP2B6). This activity may reduce the level of certain cold or flu medicines in the blood if those medicines are metabolized by the same enzymes. Patients and providers can review the active ingredients of cold and flu preparations against the official warnings for this drug.

Q: Can people with high blood pressure take Novocalmin?

A: Official safety data notes that a temporary drop in blood pressure (hypotension) is listed as an uncommon adverse effect of Novocalmin. While high blood pressure itself is not listed as a contraindication, patients with blood pressure conditions may need to consider this potential adverse effect, as detailed in the official product information.

Q: Is Novocalmin safe for older adults?

A: Regulatory guidelines indicate that older adults may use Novocalmin, but their use is subject to special considerations. Official prescribing information states that a dose reduction or an extension of the time between doses is often required for this population due to potential changes in how the body eliminates the medicine.

Q: What is the difference between Novocalmin and Aspirin?

A: Novocalmin is a pyrazolone derivative, a different pharmacological class than Aspirin (Acetylsalicylic Acid or ASA), which is a Non-Steroidal Anti-Inflammatory Drug (NSAID). Official interaction data also notes that Novocalmin may interfere with the intended antiplatelet (blood thinning) effect of low-dose Aspirin.

Q: What are the signs of an allergic reaction to Novocalmin?

A: Official safety documents warn about serious hypersensitivity reactions, which may include signs such as difficulty breathing (bronchospasm), severe widespread skin reactions like a fixed drug eruption, and potentially life-threatening anaphylactic shock. These reactions are documented safety risks that can occur upon administration.

Q: Is the onset of action different for different forms of Novocalmin (e.g., tablet vs liquid)?

A: Studies show that the rate at which the active substance is absorbed into the system, known as bioavailability, can differ depending on the form administered. Official pharmacokinetic data documents varying absorption rates for tablets, liquid solutions (drops), and suppositories.

Q: Does Novocalmin interact with psychiatric medications?

A: The official drug interaction profile explicitly lists some psychiatric medicines, such as the antidepressants Sertraline and Bupropion, as having potentially reduced effectiveness. This is because Novocalmin can induce (speed up) the activity of certain liver enzymes responsible for metabolizing these drugs.

Q: How quickly does Novocalmin start working?

A: According to official pharmacokinetic studies, the main active substance reaches its peak concentration in the bloodstream approximately 1.4 to 2.0 hours after an oral dose. The measurement of peak concentration indicates the time when the active substance is most present in the bloodstream.

Q: How long do the effects of Novocalmin last?

A: The therapeutic effect of a single administration is described in official product information as generally lasting for approximately 4 to 6 hours.

Q: Is Novocalmin a prescription drug?

A: The official regulatory status of Novocalmin's active ingredient, Sodium Metamizole, varies widely around the world. Depending on the country or jurisdiction, official guidelines may specify that it is available either only by prescription or as an over-the-counter medicine.

Q: Does Novocalmin cause drowsiness?

A: While the safety profile does not explicitly list drowsiness (sleepiness) as a common effect, it does include dizziness as a potential side effect. Regulatory information suggests that caution is warranted regarding activities that require full alertness.

Q: Can Novocalmin be taken with blood thinners like warfarin?

A: Official documents note that Novocalmin is an enzyme inducer that speeds up the metabolism of many other medicines. If co-administered with certain blood thinners, this induction activity may potentially reduce their effectiveness, necessitating careful monitoring as outlined in regulatory warnings.

Q: Is there a generic version of Novocalmin available?

A: Yes, the active component of Novocalmin is the internationally known compound Sodium Metamizole (also called Dipyrone or Analgin). This active ingredient is the basis for many generic and branded products sold across various countries.

Q: What happens if I accidentally take more Novocalmin than recommended?

A: Official guidance documented in clinical texts suggests management protocols often involve supportive measures and steps such as gastrointestinal decontamination, in cases of excessive intake or overdose.

Q: Does Novocalmin interact with birth control pills?

A: Official product information classifies Novocalmin as an enzyme inducer, meaning it can lower the level of certain medicines in the bloodstream. Since many hormonal birth control pills are metabolized through these pathways, there is a theoretical potential for reduced efficacy for co-administered oral contraceptives.

Q: Is it normal to feel a little dizzy after taking Novocalmin?

A: Yes, feeling dizzy is listed in the official regulatory safety profile as one of the common side effects reported by patients who use Novocalmin. This is typically a transient effect that is monitored as part of the known safety information.

Q: Does Novocalmin contain lactose or gluten?

A: The non-active ingredients (excipients) can vary depending on the specific form and manufacturer of Novocalmin. Official labeling for certain formulations has identified the presence of substances like lactose, which may be relevant for patients with specific intolerances.

Q: Can Novocalmin cause stomach upset?

A: Official safety data lists nausea and upset stomach among the common side effects reported by patients. These gastrointestinal symptoms are typically mild but are included in the overall documented safety profile.

Q: Can I take Novocalmin if I have asthma?

A: Official warnings highlight a risk of serious hypersensitivity reactions, including bronchospasm (narrowing of airways) and anaphylaxis. Regulatory documents specifically note that this risk is heightened in individuals with pre-existing conditions like asthma.

Q: Are there different strengths of Novocalmin available?

A: Yes, Novocalmin is marketed in multiple dosage strengths to accommodate various needs. For example, common oral forms often include different strengths of the active ingredient, such as 250 mg and 500 mg tablets, as well as other available forms like injectable solutions.

Q: What is Novocalmin's official safety classification from the FDA?

A: The active ingredient in Novocalmin, Sodium Metamizole, is not currently approved or marketed in the United States. Therefore, it does not have an official FDA safety classification for approved use within that jurisdiction.

Q: Does Novocalmin affect my ability to drive?

A: Official product information cautions that the occurrence of central nervous system side effects like dizziness in some patients means there is a need for caution. Patients are advised to note how the medicine affects them before engaging in activities that require full attention.

Q: How soon after stopping Novocalmin will it be cleared from my system?

A: Official pharmacokinetic data for the main active metabolite indicates it has an elimination half-life of approximately 2.6 to 3.5 hours. The half-life describes the time required for the concentration of the substance to drop by half in the body.

How should Novocalmin be stored and disposed of?

How to Store and Dispose of Novocalmin

Official regulatory documents define mandatory storage and disposal requirements for Novocalmin (Sodium Metamizole) to maintain product quality and safety.

Required Storage Conditions

Novocalmin must typically be stored below 25°C and should not be refrigerated or frozen, particularly injectable solutions. The medicine must be protected from light and kept in its original, tightly closed container in a dry place. All forms must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Novocalmin must not be thrown into household waste or wastewater. Disposal must be performed according to local regulations, typically by taking the product to a designated pharmaceutical waste or drug take-back point.

Novocalmin